Press release
Metastatic Colorectal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
Explore our latest breakthroughs in Metastatic Colorectal Cancer Research. Learn more about our innovative pipeline today! @ Metastatic Colorectal Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report
* July 2024:- AbbVie- A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer. Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given in combination with Fluorouracil, Folinic Acid, and Bevacizumab to adult participants to treat unresctable metastatic colorectal cancer.
* June 2024:- Mirati Therapeutics Inc.- A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1. This study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 (adagrasib) is an orally-available small molecule inhibitor of KRAS G12C.
* DelveInsight's Metastatic Colorectal Cancer pipeline report depicts a robust space with 130+ active players working to develop 140+ pipeline therapies for Metastatic Colorectal Cancer treatment.
* The leading Metastatic Colorectal Cancer Companies such as Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
* Promising Metastatic Colorectal Cancer Pipeline Therapies such as ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.
Stay informed about the cutting-edge advancements in Metastatic Colorectal Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ Metastatic Colorectal Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Colorectal Cancer Emerging Drugs Profile
* Adagrasib (MRTX849): Mirati Therapeutics
Adagrasib (MRTX849) is an investigational, highly selective and potent, oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRASG12C mutation. Adagrasib is being explored as a monotherapy as well as in combination with other anticancer drugs. The goal is to optimize efficacy and prevent treatment resistance, ensuring these potentially promising combination therapies can help patients throughout the course of their treatment journey. Extensive preclinical studies showed that combining adagrasib with a broad range of therapies, including PD-1, SHP2, Pan-EGFR, CDK 4/6, and SOS1 inhibitors, resulted in even more robust anti-tumor activity.
* QL-1203: Qilu Pharmaceutical
QL-1203, is an investigational drug being developed by Qilu Pharmaceutical. QL-1203, acts as an epidermal growth factor receptor modulator. It belongs to the class of monoclonal antibodies. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Metastatic colorectal cancer.
* ZN-c3: Zentalis Pharmaceuticals
ZN-c3 is an oral inhibitor of WEE1 in development for the treatment of advanced solid tumors. The inhibition of WEE1, a DNA damage response protein, aims to generate sufficient DNA damage in cancer cells, causing cell death, thereby preventing tumor growth and potentially causing tumor regression. Zentalis is currently conducting a Phase 1/2 clinical trial in patients with Metastatic Colorectal Cancer. In addition, the Company is also conducting a Phase 1b trial evaluating ZN-c3 in combination with chemotherapy in patients with advanced ovarian cancer.
Learn more about Metastatic Colorectal Cancer Drugs opportunities in our groundbreaking Metastatic Colorectal Cancer Research and development projects @ Metastatic Colorectal Cancer Unmet Needs [https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic colorectal cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
* Molecule Type
Metastatic Colorectal Cancer Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Discover the latest advancements in Metastatic Colorectal Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of oncology disease @ Metastatic Colorectal Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Colorectal Cancer Companies
Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
Scope of the Metastatic Colorectal Cancer Pipeline Report
* Coverage- Global
* Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Metastatic Colorectal Cancer Companies- Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
* Metastatic Colorectal Cancer Pipeline Therapies- ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.
For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Colorectal Cancer Pipeline on our website @ Metastatic Colorectal Cancer Drugs and Companies [https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Introduction
2. Executive Summary
3. Metastatic colorectal cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic colorectal cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Metastatic colorectal cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. MRTX849: Mirati Therapeutics
11. Drug profiles in the detailed report.....
12. Mid Stage Products (Phase II)
13. AK-112: Akeso Biopharma
14. Drug profiles in the detailed report.....
15. Early Stage Products (Phase I)
16. SY 5609: Syros Pharmaceuticals
17. Drug profiles in the detailed report.....
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report.....
21. Inactive Products
22. Metastatic colorectal cancer Key Companies
23. Metastatic colorectal cancer Key Products
24. Metastatic colorectal cancer- Unmet Needs
25. Metastatic colorectal cancer- Market Drivers and Barriers
26. Metastatic colorectal cancer- Future Perspectives and Conclusion
27. Metastatic colorectal cancer Analyst Views
28. Metastatic colorectal cancer Key Companies
29. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-colorectal-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Colorectal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight here
News-ID: 3564773 • Views: …
More Releases from ABNewswire
AI and the Future of the Translation Profession - Translation Conference to Deli …
Want to work smarter with AI - not just "go with the flow"? At the conference we'll share tools, methods, and practical workflows from the field - not just theory. Upgrade your professional toolkit.
The 2026 ITA hybrid translation conference will focus on one of the most urgent needs of today's language professionals: practical, applicable knowledge for working effectively - and responsibly - with artificial intelligence in real-world translation environments.
While public…
Caliente Brands Brings Bold Heat to Premium Beef Jerky Market with Authentic Spi …
Caliente Brands, LLC launches CalienteJerky.com, offering hickory-smoked beef jerky crafted exclusively from 100% USDA Approved Beef with uniquely spicy flavor profiles. The veteran-owned company targets consumers seeking bold, adventurous snack options with flavors ranging from Spicy Peppered to innovative Spicy Birria, delivering what the brand promises: where smoky and spicy meet delicious.
Caliente Brands, LLC has officially entered the premium beef jerky market with a clear mission: to deliver authentic spicy…
Patio Elegance Expands Luxury Collection to Create the Ultimate High-End Outdoor …
Patio Elegance announces an expanded portfolio of premium outdoor living solutions, ranging from professional-grade kitchen islands and grills to advanced wellness installations like cold plunges, jacuzzis, and handcrafted saunas. This comprehensive collection allows homeowners to design fully integrated, resort-style environments focused on culinary excellence, restorative wellness, and sophisticated comfort.
Patio Elegance is transforming how affluent homeowners approach outdoor living by offering a complete suite of luxury products that turn ordinary backyards…
DallasFortWorthInsurance.com Launches as the Premier Online Destination for DFW …
DallasFortWorthInsurance.com, a new venture from the trusted Baxter Insurance Agency, Inc., is now live, offering a comprehensive platform for Dallas-Fort Worth residents to easily compare and secure the best rates on auto, home, and life insurance.
DALLAS-FORT WORTH, TX - Jan 10, 2026 - Baxter Insurance Agency, Inc., a cornerstone of the Texas insurance community for over four decades, is proud to announce the launch of its latest website, DallasFortWorthInsurance.com. This…
More Releases for Metastatic
Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025?
The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound…
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market?
The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The…
Prominent Metastatic Breast Cancer Treatment Market Trend for 2025: Advancements …
Which drivers are expected to have the greatest impact on the over the metastatic breast cancer treatment market's growth?
The increasing occurrence of breast cancer is anticipated to boost the progression of the metastatic breast cancer treatment market. Breast cancer is a form of the disease that originates in the breast cells and is caused by abnormal cell growth in the breast, leading to the formation of a tumor. This alteration…
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size?
The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer…
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer.
Download Report:
https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination
One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control…
